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The clinical management of pancreatic disease is often hampered by a lack of tissue diagnosis. Endoscopic pancreatography offers the
opportunity to investigate exfoliated cells. However, the significance of mere cytological investigation is compromised by an
insufficient sensitivity. The evaluation of the molecular background of carcinogenesis hopefully is capable of providing more sensitive
diagnostic markers. The p16INK4a-/retinoblastoma tumour-suppressive pathway has been shown to be involved in the development
of near to all pancreatic neoplasms. p14ARF is another tumour suppressor located in the immediate neighbourhood of p16INK4a.
Promoter methylation has been demonstrated to be a major inactivating mechanism of both genes. We sought to further evaluate
the role of the gene locus INK4a methylation status in the endoscopic differentiation of chronic inflammatory and neoplastic
pancreatic disease. Pancreatic fluid specimens of 61 patients with either pancreatic carcinoma (PCA: 39), chronic pancreatitis (CP: 16)
or a normal pancreatogram (NAD: 6) were retrieved. In order to detect methylation of either the p14ARF or the p16INK4a
promoter a methylation-specific PCR protocol was applied. While 19 out of 39 patients with PCA showed p16 promoter
methylation (49%), none of the 16 patients with CP revealed p16 promoter methylation. p14ARF methylation was found in a lower
percentage of PCA specimens and in none of the samples of patients with CP. These results suggest a specific significance of INK4a
for the development of malignant pancreatic disease. Our data further indicate a potential role for INK4a methylation as a diagnostic
marker in the endoscopic differentiation of benign and malignant pancreatic disease.
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The diagnosis of pancreatic cancer in time for cure is still difficult.
Clinical symptoms generally only occur in advanced stages of the
disease, while no efficient screening tests are available. Further-
more, malignant and benign diseases of the pancreas are difficult
to distinguish by even sophisticated imaging procedures or
biochemical means requiring surgical diagnosis in a substantial
portion of cases. Thus, the prognosis of pancreatic cancer, in spite
of improvements, is still fatal, with less than 5% of patients
surviving more than 5 years (Niederhuber et al, 1995; Parker et al,
1996).
Pancreatic carcinoma being a ductal disease, sheddering tumour
cells with physiological pancreatic secretions into the accessible
duodenum has inspired cytology-based diagnostic concepts for
decades (Lemon and Byrnes, 1949; Gibbs, 1963). Retrograde
pancreatography by a duodenoscope for the first time offered the
opportunity to obtain directly ductal juice and to achieve tissue
diagnosis in pancreatic disease in a minimal invasive manner
(Endo et al, 1974; Hatfield et al, 1976). A multitude of studies have
demonstrated that the joint application of endoscopy and
cytotechniques has the capability to contribute to an improved
clinical management (Tatsuta et al, 1983; Venu et al, 1990; Ryan,
1991; Nakaizumi et al, 1995; Enayati et al, 1996). However, while
being characterised by a near 100% specificity, the sensitivity of
pancreatic juice cytology proved to be unsatisfying because of an
often low cell count or cell disintegration (Ferrari et al, 1994).
Hence, there is a considerable interest in molecular markers that
might complement conventional cytotechniques. The demands a
molecular candidate marker had to meet were (1) a high
prevalence in the tumour under investigation, (2) a high specificity
for malignant disease and (3) the methodological possibility to
detect reliably those alterations in routinely obtained fluid
specimens.
In pancreatic cancer, point mutations of the k-ras oncogene
have been shown with a prevalence of up to 90% (Almoguera et al,
1988; Hruban et al, 1993; Urban et al, 1993). Several studies have
demonstrated the possibility to detect these mutations in
pancreatic juice specimens or duodenal fluid (Tada et al, 1993;
Tru ¨mper et al, 1994; Berthelemy et al, 1995; Van Laethem et al,
1995). However, further work revealed that k-ras mutations are
also associated with benign or precancerous ductal lesions of
unclear prognostic significance, thus limiting the clinical signifi-
cance of detected k-ras mutations (Yanagisawa et al, 1993; Tada
et al, 1996; Furuya et al, 1997).
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yMost human cancer cells are characterised by a disruption of
p53- and Rb-tumour suppressive pathways (Sherr, 1996). The
uniquely organised ARF/INK4a locus on chromosome 9p harbours
two distinct genes, p14ARF and p16INK4a, each one encoding a
key member of both pathways, respectively (Chin et al, 1998). Both
genes share a common exon, but are under the control of their own
specific promoters. The first exon of p14ARF, designated as exon
1b, is located approximately 23kb upstream of the first exon 1a of
p16INK4a (Quelle et al, 1995; Kamijo et al, 1997). In a variety
of human malignancies, p16INK4a alterations apparently are a
major cause of Rb pathway impairment. The p16INK4a tumour
suppressor gene encodes a cyclin-dependent kinase inhibitor,
preferentially binding to CDK4 and CDK6, preventing the coupling
of those kinases with d-type cyclins and thus the activating
phosphorylation of Rb. Therefore, the functional impairment of
p16INK4a is suggested to lead to uncontrolled cell cycle
progression and neoplastic transformation (Sherr, 1996; Chin
et al, 1998). p14ARF, on the other hand, by accumulating evidence
is suggested to act as a tumour suppressor by neutralising MDM2-
mediated degradation of p53 (Pomerantz et al, 1998; Stott et al,
1998; Zhang et al, 1998). For pancreatic carcinoma, it has been
reported that the Rb tumour-suppressive pathway is abrogated in
near to all studied cases and that this disruption is caused
exclusively by inactivation of the p16INK4a gene. Herein, aberrant
promoter methylation proved to be a major inactivating mechan-
ism (Schutte et al, 1997). While de novo promoter methylation of
p14ARF has been reported to occur in some gastrointestinal
malignancies like stomach and colorectal cancer and precancerous
conditions (Barrett et al, 1996; Hsieh et al, 1998; Klump et al, 1998;
Esteller et al, 2000; Song et al, 2000; Iida et al, 2000), only a few data
exist regarding the situation in pancreatic adenocarcinoma.
The present study sought to further evaluate the significance of
aberrant p16INK4a and p14ARF promoter methylation as detected
in endoscopically obtained fluid specimens in the differential
diagnosis of pancreatic disease. Pancreatic or biliary fluid samples
of patients with chronic pancreatitis, pancreatic cancer or missing
alterations were analysed with respect to the methylation status of
the ARF/INK4a locus in order to define the prevalence and
specificity of those epigenetic alterations.
PATIENTS AND METHODS
Patients and specimens
In all, 57 patients in four endoscopic units, who were routinely
investigated by endoscopic retrograde cholangiopancreatography
(ERCP), were enrolled into this study (37 pancreatic carcinoma
(PCA), 14 chronic pancreatitis (CP), six nothing abnormal detected
(NAD)). The study was approved by the local ethical committees.
The median age of patients with PCA and CP was 70.2 years (39–
90 years) and 51.6 years (23–74 years), respectively. The individual
diagnosis of pancreatic disease was based on unequivocal
histological, biochemical, radiological results and the immediate
clinical course. Owing to the often mere palliative treatment of
patients with pancreatic adenocarcinoma tissue diagnosis was not
available in 18 patients diagnosed to have pancreatic cancer. If a
malignant disease other than of pancreatic origin could not
definitely be ruled out, samples were excluded from further
molecular analysis. Since no standardised protocol in regard to
cytological diagnosis was applied and some patients already had a
confirmed diagnosis of malignancy when endoscopy was per-
formed, aspirates for cytology were not retrieved in all patients.
Thus, malignancy was confirmed in just four patients by cytology.
Investigators were asked to try to cannulate the pancreatic duct
and aspire pancreatic fluid; in case of technical difficulties it was
allowed to either aspire secretions from the Ampulla vateri orFin
the case of a supposed infiltration–of the common bile duct. After
wire-guided cannulation of the pancreatic duct, between 1 and 3ml
of pancreatic secretion was aspirated. No stimulation by intrave-
nous administration of secretin was performed. No standardised
strategy with regard to the exact localisation of the catheter tip was
followed. In a few cases, pancreatic fluid was aspired through a
prior inserted external drainage of the major pancreatic duct.
Immediately after aspiration, obtained specimens were stored
without any further processing at  201C. Additionally, 12 tissue
specimens of pancreatic cancer were included. In some patients
who were submitted to surgery or had diagnostic biopsy archival
tissue specimens, both pancreatic secretions and tissue specimens
were analysed.
DNA extraction
Genomic DNA was extracted from thawed specimens. A volume of
1ml of secretion was digested for 3 days at 551C using a proteinase
K/sodium dodecyl sulphate (SDS) solution. DNA was extracted
using the conventional phenol/chloroform method.
Methylation-specific PCR amplification
A slight modification of the protocol suggested by Herman et al
(1996) has been implemented. In brief, DNA modification by
bisulphite converts exclusively unmethylated cytosines to uracil.
Subsequent PCR amplification with primers specific for unmethy-
lated vs methylated DNA reveals the methylation status of
investigated DNA sections. Initially, 1mg of DNA was denatured
in a volume of 50ml (final NaOH concentration 0.2 M) for 20min at
371C. A total of 30ml hydroquinone (Sigma, Deisenhofen,
Germany) (10mM) and 520mlo f3 M sodium bisulphite (Sigma,
Deisenhofen, Germany) at pH 5.5 were added and mixed. Samples
were incubated at 551C for 21h. Modified DNA was purified using
a commercially available PCR-Purification Kit according to the
manufacturer’s recommendations (Qiagen, Hilden, Germany).
Finally, a second NaOH treatment was performed (20min, room
temperature, final concentration 0.3 M). Modified and purified
DNA was precipitated by ethanol for 12h and resuspended in
100ml of water. Primer pairs for PCR amplification are given in
Table 1 and were purchased (MWG-Biotech, Ebersberg, Germany).
A volume of 100ml PCR mixtures contained 10ml buffer (10mM
Tris-HCl, 50mM KCl, 0.1% Triton X-100), 1ml of MgCl2, 1.5mlo f
dNTPs (1.25mM), primers, 2U of Taq polymerase (PAN-Systems,
Aidenbach, Germany), and 0.1mg of DNA. Amplification was
performed in a thermal cycler (Biometra, Go ¨ttingen, Germany) for
35 cycles (951C/5min, annealing temperature/90s, 721C/60s) and
concluded by a final 8min extension at 721C. A control without the
addition of DNA was performed for each PCR set. A volume of
20ml of PCR product was loaded onto nondenaturing polyacryla-
mide gels (8%) and visualised by silver staining. A methylation was
confirmed if at least two experiments had demonstrated an
unequivocal amplification product of methylation-specific PCR.
Table 1 Primer pairs
p14 U FW TTTTTGGTGTTAAAGGGTGGTGTAGT
p14 U RV CACAAAAACCCTCACTCACAACAA
p14M FW GTGTTAAAGGGCGGCGTAGC
p14M RV AAAACCCTCACTCGCGACGA
p16 U FW TTATTAGAGGGTGGGGTGGATTGT
p16 U RV CAACCCCAAACCACAACCATAA
p16M FW TTATTAGAGGGTGGGGCGGATCGC
p16M RV GACCCCGAACCGCGACCGTAA
U=specific for unmethylated DNA, M=specific for methylated DNA.
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without clinical information on singular specimens.
Statistical analysis
The association of p16INK4a and p14ARF promoter methylation
in malignant vs nonmalignant pancreatic disease and patients with
a normal pancreatogram was tested by w
2 test and Yates’
correction.
RESULTS
p16-promoter methylation
In total, 43.2% of specimens obtained from patients with
pancreatic carcinoma revealed p16 promoter methylation (16 out
of 37). However, none out of 16 specimens obtained from patients
with chronic pancreatitis (n¼14) or missing alterations (n¼6)
showed p16 promoter methylation. Thus, a sensitivity of 43.2%
and a specificity of 100% in regard to the detection of malignancy
has been found for p16 promoter methylation (Figure 1, Tables 2
and 3).
p14-promoter methylation
Methylation of the p14 promoter was detected in 20.6% of
specimens of patients with pancreatic carcinoma (seven out of 34).
Promoter methylation of p14ARF could neither be detected in
specimens obtained from patients with chronic pancreatitis nor in
those samples from patients with missing alterations. Thus, a
sensitivity of 20.6% and a specificity of 100% in regard to the
detection of malignancy has been shown for p14 promoter
methylation (Figure 1, Tables 2 and 3).
Relation of p14 and p16 promoter methylation
A simultaneous promoter methylation of p14ARF and p16INK4a
was seen in 14.7% of the specimens from patients with pancreatic
carcinoma. A simultaneous methylation of the adjacent p14ARF
promoter was seen in 22% of those specimens with positive
p16INK4a methylation (Table 2). An exclusive methylation of
either the p16INK4a or the p14ARF promoter region was observed
in 72 and 43% of methylation-positive carcinoma specimens,
respectively.
Figure 1 Gels with products of PCR specific for either an unmethylated
(U) or a methylated (M) promoter region
Table 2 Methylation data within pancreatic secretions and/or tissue
specimens
Pancreatic secretion Tissue
No. Diagnosis p14M p16M p14M p16M
1 PCA n n n n
2 PCA n n n n
3 PCA n y n n
4 PCA n n y y
5 PCA n n n y
6 PCA nd n n n
7 PCA nd nd n n
8 PCA nd nd n n
9 PCA nd nd N n
10 PCA nd nd y n
11 PCA nd nd y y
12 PCA nd nd n n
13 PCA n n nd nd
14 PCA nd n nd nd
15 PCA y y nd nd
16 PCA n n nd nd
17 PCA n y nd nd
18 PCA n y nd nd
19 PCA n y nd nd
20 PCA n n nd nd
21 PCA n y nd nd
22 PCA y y nd nd
23 PCA n n nd nd
24 PCA n y nd nd
25 PCA n n nd nd
26 PCA n n nd nd
27 PCA nd y nd nd
28 PCA n y nd nd
29 PCA y y nd nd
30 PCA y n nd nd
31 PCA y n nd nd
32 PCA n y nd nd
33 PCA n n nd nd
34 PCA n n nd nd
35 PCA y y nd nd
36 PCA n n nd nd
37 PCA n y nd nd
38 PCA n n nd nd
39 PCA n n nd nd
40 PCA y y nd nd
41 PCA n n nd nd
42 PCA n n nd nd
43 PCA n y nd nd
44 CP n n nd nd
45 CP n n nd nd
46 CP n n nd nd
47 CP n n nd nd
48 CP n n nd nd
49 CP n n nd nd
50 CP n n nd nd
51 CP n n nd nd
52 CP n n nd nd
53 CP n n nd nd
54 CP n n nd nd
55 CP n n nd nd
56 CP n n nd nd
57 CP n n nd nd
58 NAD n n nd nd
59 NAD n n nd nd
60 NAD n n nd nd
61 NAD n n nd nd
62 NAD n n nd nd
63 NAD n n nd nd
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Molecular approaches keep the promise of complementing
cytotechniques in the noninvasive diagnosis of pancreaticobiliary
disease. The potential sensitivity of any molecular alteration,
however, is defined by its prevalence in pancreatic cancer, its
specificity for malignant alterations and the technical options to
detect it reliably.
The methodological success of PCR-based approaches towards
the molecular analysis of pancreatic fluids is limited by polymerase
inhibitors. Like other groups, we observed the frequent failure of
PCR analysis in pilot studies (Saurin et al, 2000). In our experience,
it is essential to find out the least possible amount of DNA allowing
PCR amplification. However, our preliminary studies revealed
that methylation analysis, even though requiring additional
processing steps and being a gradual process, is even
more reproducible in endoscopically obtained secretions than
mutational screening assays as PCR-SSCP or PCR-RFLP. The
present study is the first to demonstrate the diagnostic potential of
INK4a methylation in pancreatic secretions obtained during
routine endoscopic retrograde pancreatography. Methylation
status of both the p14ARF and the p16INK4a promoter was
successfully assessed in all samples enclosed. Surprisingly, unlike
the results of a previous preliminary analysis, the localisation of
the catheter tip did not influence the prevalence of detected
methylation. We speculate that exfoliated cells were not only
present in the pancreatic duct or Ampulla vateri, but also in the
common bile duct due to an infiltration of the biliary system with a
‘double duct sign’ detectable in most cases. However, it is to be
assumed that due to a very small number of patients in our study a
difference in technical approaches towards aspiration of secretions
was missed.
Interestingly, the methylation rates detected in tissue proved
to be somewhat lower than those detected in endoscopically
retrieved pancreatic secretions. While it seems intriguing
to speculate on whether fluid samples retrieved from the
pancreatic duct might be even more representative than tissue
slices from tumour blocks, it has to be taken into consideration
that (1) the numbers of patients in whom tissue could be analysed
were small and (2) no standardised protocol in regard to
the retrieval and storage of tissue specimens was followed;
detected methylation rates could be lower due to degradation of
DNA and/or contamination with benign ductal or stromal cells in
archival paraffin blocks.
De novo p16INK4a promoter methylation was detected in
43.2% of specimens from patients with pancreatic carcinoma.
These data parallel those recently reported by Schutte et al (1997),
who detected p16INK4a promoter methylation in six out of
17 primary pancreatic carcinoma specimens or pancreatic
carcinoma cell lines (35%). Similarly, a prevalence of p16INK4a
methylation of 38% has recently been reported by Esteller et al
(2001). In this context, it needs to be emphasised that exclusively
exocrine pancreatic adenocarcinomas of ductal origin have been
included. A recent study published by Moore et al (2001) has
addressed p16 alterations in primary neoplasms of the pancreas,
and these data have shown that in exocrine and endocrine
tumourigenesis of the pancreas different molecular pathways may
be involved.
The situation for p14ARF is more controversial. As far as we
know, up to this end the only data regarding the role of p14ARF in
pancreatic carcinoma have been published also by Esteller et al
(2000): in none out of 20 randomly selected pancreatic carcinomas
p14ARF promoter methylation was detected. This is in apparent
contrast to our findings, showing a prevalence of at least 20.6% in
36 pancreatic fluid specimens. While it is well recognised that
promoter methylation is a gradual process, our results could
reflect a weak methylation of unknown functional significance. In
addition, a ‘background level of methylation’ had also been
reported by Schutte et al (1997) in normal duodenal tissue.
Moreover, there is an ongoing controversy as to whether age-
related methylation possibly may also involve promoter regions of
tumour-suppressive genes. It is to be acknowledged that patients
with pancreatic carcinoma tend to be older than patients with
chronic pancreatitis. Thus, a contribution of age-related methyla-
tion may not be ruled out when higher rates of promoter
methylation are detected in neoplasms. And indeed in this study,
for p16 promoter methylation a lower frequency in patients 63
years and younger was detected, while patients of 80 years and
older revealed a methylated promoter more frequently than the
group as a whole. However, for p14 methylation in older patients
an even lower frequency of methylation was detected (data not
shown).
Taken together, at the moment it may be postulated
that p14ARF promoter methylation is at least rarer than
p16INK4a methylation in pancreatic carcinoma and that further
evaluation of p14ARF’s exact role in the development and
course of pancreatic carcinoma requires further studies in greater
patient cohorts, bringing together methylation data with functional
findings.
In none of the specimens obtained from patients with chronic
pancreatitis, either p16INK4a or p14ARF promoter methylation
was detected in this study. This further supports the results of
our own previous work and the data reported by others indi-
cating that the tumour-suppressive function of p16INK4a is
exclusively abrogated in (pre-)neoplastic but not in merely
inflammatory or hyperproliferative conditions (Barrett et al,
1996; Hsieh et al, 1998; Klump et al, 1998). However, it is well
recognised from epidemiological and histopathological studies that
chronic pancreatitis may predispose for the development of
pancreatic cancer. Thus, the prevalence of INK4a methylation in
preneoplastic ductal lesions requires further evaluation. For
pancreatic disease our findings are in fortunate contrast to
Table 3 Results of methylation analysis (p14M, p16M) in secretions for pats without
clinical signs of pancreatic disease (NAD), chronic pancreatitis (CP), or pancreatic
carcinoma (PCA)
NAD CP PCA
p14M 0/6 (0%) 0/14 (0%) 7/34 (20.6%)
P>0.1 (w
2=3.16)/n.s.
Pancreatic
duct
Other tip
localisation
Pancreatic
duct
Other tip
localisation
0/12 0/2 2/13 5/21
p16M 0/6 (0%) 0/14 (0%) 16/37 (43.2%)
Po0.01 (w
2=11.91)
Pancreatic
duct
Other tip
localisation
Pancreatic
duct
Other tip
localisation
0/12 0/2 6/14 10/23
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evaluation of INK4a methylation in the management of unclear
pancreatic disease.
Taken together, our findings for the first time demonstrate the
technical feasibility to detect INK4a’s methylation in pancreatic
secretions. Moreover, the high prevalence of p16INK4a methyla-
tion found in pancreatic carcinoma tissues is confirmed by these
data. INK4a methylation revealed a 100% specificity for malignant
pancreatic disease in this study. p14ARF methylation apparently is
of subordinate significance in pancreatic carcinoma while its exact
role needs to be further evaluated.
We would conclude, therefore, that INK4a methylation is a
promising candidate marker for the endoscopic differential
diagnosis of malignant and benign pancreatic disease.
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